Opendata, web and dolomites

V-LAP

Saving millions of lives by enabling an effective treatment for Heart Failure patients; V-LAP, a revolutionary, miniaturized implant and its dedicated wearable device.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

hf    30    flow    healthcare    causes    lap    measured    levels    implantable    red    minimally    ineffective    coupling    adhf    tiredness    28    hospitalization    detecting    powered    back    belt    green    meet    clinical    plan    acute    left    leg    ac    diabetes    collected    prescription    earliest    invasively    outcome    efficacy    hospital    excess    decreasing       yellow    pressure    glucose    catheter    people    takes    swelling    body    ventricular    company    heart    vectorious    worn    patients    mortality    worsening    edema    chronic    external    inductive    clothes    trials    sent    decompensate    data    worldwide    min    disruptive    synchronize    hemodynamic    promptly    organs    fluids    patents    total    symptoms    65    transition    color    battery    adjust    invasive    dyspnea    procedure    free    unable    code    nhs    ing    provider    predict    12    device    filling    lv    quality    life    global    covered    least    threatening    trough    events    98    miniaturized    aged    daily    pump    monitor    day    sudden    expenditure    completely    mobile    medications    industrialization    portfolio    weeks    blood    public    clinicians    indicator    patient    website   

Project "V-LAP" data sheet

The following table provides information about the project.

Coordinator
VECTORIOUS MEDICAL TECHNOLOGIES LTD 

Organization address
address: RAUL WALLENBERG 24
city: TEL AVIV JAFFA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.vectoriousmedtech.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VECTORIOUS MEDICAL TECHNOLOGIES LTD IL (TEL AVIV JAFFA) coordinator 50˙000.00

Map

 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed trough a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/ red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes. During Phase 1 project the Company will assess scale-up industrialization plan, product development and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

Gestoos (2017)

The first Behavior Recognition Open Platform

Read More  

OKIDOKEYS (2015)

New electro-mechanic access system with dematerialized keys for residential market

Read More